UAB is more common in older adults. The prevalence of UAB increases with age, and it is estimated that up to 20% of adults over the age of 65 have UAB. UAB can be caused by a number of factors, including neurological disorders, medications, and surgery. UAB can be a difficult condition to live with. It can lead to a number of problems, including urinary incontinence, urinary tract infections, and social isolation. There is no cure for UAB. However, there are a number of treatments available that can help to improve symptoms and improve quality of life.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-underactive-bladder-market
Data Bridge Market Research analyses that the Underactive Bladder Market will grow at a CAGR of 5.10% in the forecast period of 2022 to 2029 and is expected to reach USD 1,286.59 million by 2029 from USD 864.20 million in 2021. The prevalence of underactive bladder (UAB) is increasing due to a number of factors, including aging, neurological disorders, and medications. The global prevalence of UAB is estimated to be 10-15% in adults over the age of 65. There is a growing awareness of UAB among the general public and healthcare professionals. This is leading to more people being diagnosed with UAB, and it is also leading to more people seeking treatment for UAB. There have been significant advances in the treatment options for UAB in recent years. These advances include new medications, devices, and surgical procedures. These new treatment options are more effective and have fewer side effects than the older treatment options. Healthcare expenditure is increasing globally, and this is providing an opportunity for the underactive bladder market. The increasing healthcare expenditure is leading to more people being able to afford treatment for UAB.
Growing demand for personalized treatments is expected to drive the market's growth rate
There is a growing demand for personalized treatments for UAB. This is due to the fact that UAB is a complex condition and different people respond differently to different treatments. Personalized treatments are designed to take into account the individual patient's needs and circumstances. The underactive bladder market is subject to stringent regulatory requirements. This is due to the fact that the products used to treat UAB are regulated as medical devices. The stringent regulatory requirements can be a challenge for market players, but they also help to ensure the safety and efficacy of the products that are available.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Astellas Pharma Inc. (Japan), Aurobindo Pharma. (India), Boehringer Ingelheim International GmbH (Germany), Macleods Pharmaceuticals Limited (India), Orion Corporation (Finland), Ono Pharmaceuticals (Japan), Novartis AG (Germany), Pfizer Inc. (U.S.), Cipla, Inc. (India), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global underactive bladder market is segmented into type, route of administration, end user, and distribution channel.
- On the basis of treatment, the market is segmented into pharmacotherapy, surgical methods, urethral assist device, and stem cell and gene therapies.
Pharmacotherapy segment is expected to dominate the underactive bladder market
The pharmacotherapy segment is expected to dominate the market with a market share of 85.67% due to rise in urologic diseases.
- On the basis of route of administration, the market is segmented into oral, parenteral, and others. Parenteral segment is expected to dominate the market with a market share of 72.85% due to rising incidences of neurogenic bladder infections.
- On the basis of end user, the market is segmented into hospitals, clinics, academic and research institutes, and others.
Hospitals segment is expected to dominate the underactive bladder market
Hospitals segment is expected to dominate the market with a market share of 56.13% due to increase in the prevalence of bladder disorders.
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others. Hospital pharmacy is expected to dominate the market with market share of 71.07% due to development of novel therapies for underactive bladder (UAB), and pipeline products enhancing its demand along with increasing investment in R&D leading to market growth.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Astellas Pharma Inc. (Japan), Aurobindo Pharma. (India), Boehringer Ingelheim International GmbH (Germany), Macleods Pharmaceuticals Limited (India), Orion Corporation (Finland), Ono Pharmaceuticals (Japan), Novartis AG (Germany), Pfizer Inc. (U.S.), Cipla, Inc. (India), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India).
Market Development
- In 2020, Astellas Pharma Europe Ltd. completed a phase 1 clinical trial of ASP8302, a novel muscarinic M3 receptor modulator, in subjects with underactive bladder (UAB). The trial was a randomized, double-blind, placebo-controlled trial that enrolled 100 subjects. The trial's primary endpoint was to assess the safety and tolerability of ASP8302. The trial found that ASP8302 was well-tolerated and that there were no serious adverse events. ASP8302 is currently under phase 2 clinical trial to investigate the efficacy of the drug in patients with UAB. The phase 2 trial is a randomized, double-blind, placebo-controlled trial that is enrolling 200 subjects. The trial's primary endpoint is to assess the efficacy of ASP8302 in improving bladder emptying in patients with UAB. The results of the phase 2 trial are expected to be available in 2023. If the trial is successful, ASP8302 could be a potential treatment for UAB.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the underactive bladder market during the forecast period 2022-2029
North America is the dominating region in the global underactive bladder market. This is due to the high prevalence of UAB in the region, as well as the increasing awareness of the condition and the availability of effective treatment options.
Asia-Pacific is estimated to be the fastest-growing region in the underactive bladder market in the forecast period 2022-2029
Asia-Pacific is expected to grow at the fastest rate of all the regions. The growth of the Asia-Pacific market is driven by the increasing geriatric population base suffering from UAB in the region and growing spending on healthcare infrastructure development.
For more detailed information about the underactive bladder market report, click here – https://www.databridgemarketresearch.com/reports/global-underactive-bladder-market
